Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

BACKGROUND: No chemotherapeutic agents have been standardised for transarterial chemoembolisation (TACE). In particular, doxorubicin has no defined optimal dosage in TACE procedures. We compared low versus currently used dose of doxorubicin for TACE in patients with hepatocellular carcinoma (HCC) in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur Radiol Exp
Main Authors: Bessar, Ahmed A., Farag, Ahmed, Abdel Monem, Sameh M., Wadea, Fady M., Shaker, Shady E., Ebada, Mahmoud Ahmed, Bessar, Manar A.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2021
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7921261/
https://ncbi.nlm.nih.gov/pubmed/33649930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41747-021-00204-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki